Table 1.
Characterization of various Lip and SLN formulations
| Formulations | Particle size (nm) | PDI | Zeta potential (mV) | Encapsulation; efficiency (%) | Drug-loading; capacity (%) |
|---|---|---|---|---|---|
| Lip | 164.8 ± 3.41 | 0.17 ± 0.02 | -9.17 ± 1.68 | — | — |
| Lip-CMN | 166.3 ± 3.11 | 0.13 ± 0.05 | -8.21 ± 1.19 | — | — |
| omLip-CMN | 170.2 ± 1.26 | 0.15 ± 0.04 | -9.88 ± 1.42 | — | — |
| Iri/Lip-CMN | 172.1 ± 2.34 | 0.17 ± 0.05 | -7.23 ± 1.26 | 85.89 ± 2.18 | 18.79 ± 1.22 |
| Iri/omLip-CMN | 175.2 ± 2.27 | 0.16 ± 0.04 | -8.18 ± 1.43 | 86.28 ± 2.29 | 19.88 ± 1.03 |
| SLN | 133.8 ± 1.65 | 0.16 ± 0.07 | 20.47 ± 2.21 | — | — |
| SLN-CMN | 136.7 ± 2.25 | 0.21 ± 0.05 | 22.15 ± 1.25 | — | — |
| omSLN-CMN | 139.9 ± 2.76 | 0.18 ± 0.04 | 18.20 ± 1.49 | — | — |
| miR-200/SLN-CMN | 143.1 ± 1.18 | 0.19 ± 0.04 | 17.88 ± 1.38 | 86.78 ± 0.56 | 18.34 ± 1.23 |
| miR-200/omSLN-CMN | 148.6 ± 0.36 | 0.12 ± 0.05 | 16.70 ± 1.69 | 87.19 ± 0.81 | 19.52 ± 1.56 |